Contribution: Industrial Research Assistance Program – Contributions to Firms
Jenthera Therapeutics Inc.
$75,000.00
ARP - MNC Collab - Immuno-Nuc-Nab - Development and Validation of CRISPR RNP delivery to Immune Cell populations
FY 2024-25 · 2024-10-01
Summary
The project will focus on developing a suite of gene editing complexes capable of delivering gene edits in vivo to specific cell types. The goal is to modify, correct, or enhance cell behaviors, enabling a wide range of new therapeutic developments in key areas. This will expand treatment options and accelerate the company's growth.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Cote-Saint-Luc|Côte Saint-Luc, Quebec, Canada
Recipient Type
For-profit organization
Business Number
701783482
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2025-03-28
Agreement Number
1023213
Agreement Start Date
2024-10-01
Agreement Title
ARP - MNC Collab - Immuno-Nuc-Nab - Development and Validation of CRISPR RNP delivery to Immune Cell populations
Agreement Title (French)
PRA - MNC Collab — Immuno-Nuc-Nab — Développement et validation de la livraison de CRISPR RNP aux populations de cellules immunitaires
Agreement Type
Contribution
Agreement Value
$75,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The project will focus on developing a suite of gene editing complexes capable of delivering gene edits in vivo to specific cell types. The goal is to modify, correct, or enhance cell behaviors, enabling a wide range of new therapeutic developments in key areas. This will expand treatment options and accelerate the company's growth.
Description (French)
Le projet se concentrera sur le développement d’une suite de complexes d’édition de gènes capables de délivrer des éditions de gènes in vivo à des types de cellules spécifiques. L’objectif est de modifier, de corriger ou d’améliorer le comportement des cellules, ce qui permettra un large éventail de nouveaux développements thérapeutiques dans des domaines clés. Cela permettra d’élargir les options thérapeutiques et d’accélérer la croissance de l’entreprise.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Mount Royal
Federal Riding (French)
Mont-Royal
Federal Riding Number
24052
NAICS Code
339110
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
701783482
Recipient City
Cote-Saint-Luc|Côte Saint-Luc
Recipient Country
CA
Recipient Legal Name
Jenthera Therapeutics Inc.
Recipient Operating Name
Jenthera Therapeutics Inc.
Recipient Postal Code
H4W 1K7
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2024-2025-Q3-1023213
